Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
GoodRx Holdings, Inc. reported first-quarter 2026 revenue of $194.0 million, down from $203.0 million a year earlier, as its core prescription transactions business declined. Net income fell to $1.2 million, with net margin narrowing to 0.6% from 5.4%.
Prescription transactions revenue dropped 24% to $113.7 million, reflecting fewer Monthly Active Consumers amid pharmacy store closures and changes in an integrated savings program. Offsetting this, Pharma Direct revenue jumped 82% to $52.2 million and subscription revenue grew 16% to $24.4 million, supported by new condition-specific subscription programs.
Adjusted EBITDA was $58.3 million, giving a 30.0% Adjusted EBITDA Margin versus 34.4% a year ago, as mix shifted and costs of newer offerings rose. GoodRx ended the quarter with $235.7 million in cash and cash equivalents, a $493.8 million term loan outstanding, and continued share repurchases under its $450 million authorization.
GoodRx Holdings, Inc. reported first quarter 2026 revenue of $194.0 million, down 4% from $203.0 million a year earlier, as lower prescription transactions offset growth in other areas. Net income was $1.2 million, compared with $11.1 million, reflecting a much lower net margin of 0.6%.
Prescription transactions revenue fell 24% to $113.7 million due to fewer Monthly Active Consumers and weaker unit economics, while Pharma Direct revenue rose 82% to $52.2 million and subscription revenue grew 16% to $24.4 million. Adjusted EBITDA was $58.3 million, or a 30.0% margin.
The company generated $11.8 million of operating cash flow, ended March 31, 2026 with $235.7 million in cash and cash equivalents and $493.8 million of total debt, and repurchased 5.5 million Class A shares for $12.6 million. For full year 2026, GoodRx guides revenue to $765–$785 million versus $796.9 million in 2025 and expects Adjusted EBITDA above $235 million, raising its prior outlook.
GoodRx Holdings, Inc. filed an initial ownership report for Chief Accounting Officer Thomas Chan. The filing shows direct ownership of 1,000 shares of Class A common stock, multiple stock options to buy Class A shares at exercise prices between $4.67 and $7.61 per share with expirations from 2032 to 2035, and several restricted stock unit awards. The options and RSUs vest in quarterly installments, generally over four-year schedules, conditioned on Mr. Chan’s continued service.
GoodRx Holdings, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders on June 16, 2026 at 12:00 p.m. Pacific Time. Stockholders of record as of April 20, 2026 may vote online, by phone, by mail, or during the live webcast.
Stockholders will vote on electing three Class III directors to terms ending at the 2029 annual meeting, ratifying the appointment of KPMG LLP as independent registered public accounting firm for 2026, and approving, on an advisory basis, the compensation of named executive officers. The Board recommends voting FOR all three proposals.
GoodRx Holdings, Inc. appointed Thomas Chan as Chief Accounting Officer and designated him as the company’s principal accounting officer, effective immediately. Chan has held increasing accounting and reporting roles at GoodRx since 2020 and previously worked in audit and assurance at Deloitte & Touche.
In connection with his promotion, Chan’s annual base salary was set at $310,000 with a target annual bonus of 40% of base salary. He will receive a restricted stock unit award valued at $131,250 and a performance-based restricted stock unit award valued at $43,750 under the 2020 Incentive Award Plan, with multi-year time- and performance-based vesting schedules tied to continued employment.
GoodRx Holdings, Inc. officer Christopher A. McGinnis exercised 36,987 restricted stock units into Class A common stock and received the same number of shares at no cash cost. Of these, 10,745 shares were withheld at $2.23 per share to cover tax obligations, leaving 152,563 Class A shares held directly. Following the transaction, 406,865 restricted stock units remained outstanding, which vest in 12 equal quarterly installments starting on April 15, 2026, subject to continued service.
GoodRx Holdings, Inc. director and officer Wendy Lynn Barnes exercised restricted stock units into Class A common stock and had shares withheld to cover taxes. She converted 277,288 restricted stock units into the same number of Class A shares at a conversion price of $0.00 per share. To satisfy tax obligations, 120,456 Class A shares were disposed of at $2.23 per share through tax-withholding transactions, which are not open-market sales. After these transactions, she directly owns 584,825 shares of Class A common stock.
GoodRx Holdings, Inc. reported governance changes following a director departure. On March 31, 2026, Ian T. Clark resigned from the Board of Directors and the Nominating & Governance Committee, stating his decision was not due to any disagreement with the company or its management.
To rebalance director classes, the Board accepted Wendy Barnes’s resignation as a Class I director and immediately re-elected her as a Class III director. Her Board service is considered uninterrupted, and the Board now has three directors in each of Classes I, II, and III.
GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey has submitted his resignation, effective April 3, 2026, to pursue other opportunities. He will remain with the company through June 8, 2026 to help transition his responsibilities. The company stated that his resignation is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for his years of service.